{
  "id": 12390336,
  "title": "STAT+: Pharmalittle: We’re reading about U.S.-funded psychedelic trials, an AstraZeneca R&D center, and more",
  "url": "https://urgent.news/2026/10/06/stat-pharmalittle-were-reading-about-u-s-funded-psychedelic-trials-an",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-06T13:36:42.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/10/06/us-funded-psychedelic-trials-astrazeneca-research-center/"
  },
  "original_language": "en",
  "account": "The U.S. government is funding clinical trials for the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder. This initiative was made possible by an executive order signed by President Trump in April, which allocated $50 million for the federal ibogaine research. The FDA has opened a public docket to gather feedback on various aspects of the trials, including trial design, dose selection, patient eligibility, safety monitoring, and study-stopping rules. AstraZeneca has expanded its presence in the U.S. market by opening a new R&D center in Cambridge, Massachusetts, as part of a $1 billion investment program in the state. The facility spans 570,000 square feet across 18 stories in the Kendall Square area, which is home to a dense cluster of biotech companies.",
  "summary": "The Trump administration is advancing the first government-funded clinical trials of the psychedelic drug ibogaine to treat opioid addiction and PTSD",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}